News archive search

Search the Newsreel

Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.

Showing
1–18
Matches
18
Sources here
11
Companies here
1
Search results Stored financial headlines

Active search

18 matching headlines

Ticker or company: PLYXMain company stories
Clear
Latest

Stock Titan Balance sheet

Polaryx Therapeutics (PLYX) cuts losses as cash rises to $11.5M

Polaryx Therapeutics, a clinical-stage biotech company, reported a narrowed net loss of $1.4 million for Q2 2026 and $3.9 million for the first half of 2026, alongside a significant increase in cash and cash equivalents to $11.5 million, primarily due to a $10 million equity financing. The company plans to initiate a Phase 2 proof-of-concept basket trial (SOTERIA) …

Main company 🇺🇸 United States
Read at Stock Titan
Sharemaestro market context Stored weekly price path 28 weeks -70.8% · Next-week setup negative 41.0% PLYX stored weekly price path from 6 Feb 2026 to 14 Aug 2026
Just inNext headlines
MarketBeat Earnings Main company 🇺🇸 United States

Polaryx Therapeutics, Inc. (NASDAQ:PLYX) Given Average Recommendation of "Moderate Buy" by Brokerages

Polaryx Therapeutics (NASDAQ:PLYX) has received a "Moderate Buy" consensus recommendation from brokerages, with an average 12-month price target of $7.67 against a current share price of $2.48. Insider ownership is significant at 45.82%, and CEO Alex Keun Mo Yang recently purchased 88,453 shares. The …

PLYX main company
Sharemaestro market context Stored weekly price path 28 weeks -70.8% · Next-week setup negative 41.0% PLYX stored weekly price path from 6 Feb 2026 to 14 Aug 2026

Search results

Matching headlines

External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.

MarketBeat Analyst action Main company 🇺🇸 United States

Polaryx Therapeutics (NASDAQ:PLYX) Coverage Initiated at Raymond James Financial

Raymond James Financial has initiated coverage on Polaryx Therapeutics (NASDAQ:PLYX) with a "strong-buy" rating and a $6.00 price target, suggesting a significant upside. This comes amidst mixed analyst opinions, though the stock holds a consensus "Moderate Buy" rating. The report also highlights recent insider …

PLYX main company
Sharemaestro market context Stored weekly price path 28 weeks -70.8% · Next-week setup negative 41.0% PLYX stored weekly price path from 6 Feb 2026 to 14 Aug 2026
Investing.com Canada Analyst action Main company 🇺🇸 United States

Raymond James initiates Polaryx Therapeutics stock with strong buy By Investing.com

Raymond James has initiated coverage on Polaryx Therapeutics (NASDAQ: PLYX) with a "Strong Buy" rating and a price target of $6.00, suggesting a significant upside. The biotechnology company is developing PLX-200 for rare pediatric lysosomal storage disorders, with a Phase 2 trial expected to …

PLYX main company
Sharemaestro market context Stored weekly price path 28 weeks -70.8% · Next-week setup negative 41.0% PLYX stored weekly price path from 6 Feb 2026 to 14 Aug 2026
富途牛牛 Market update Main company 🇺🇸 United States

Polaryx Therapeutics To Participate In The 25th Annual Needham Virtual Healthcare Conference

Polaryx Therapeutics, a clinical-stage biotechnology company, announced its participation in the 25th Annual Needham Virtual Healthcare Conference. Executives will host one-on-one investor meetings from April 13-16, 2026, and deliver a group presentation on April 16, 2026, at 10:15 a.m. ET. The company focuses on …

PLYX main company
Sharemaestro market context Stored weekly price path 28 weeks -70.8% · Next-week setup negative 41.0% PLYX stored weekly price path from 6 Feb 2026 to 14 Aug 2026
TradingKey Earnings Main company 🇺🇸 United States

Polaryx Therapeutics Ord Shs (PLYX) Earnings Forecast: Future EPS & Revenue Growth Estimates

The article provides an earnings forecast for Polaryx Therapeutics Ord Shs (PLYX), highlighting a "Buy" rating based on 3 analysts and a target price indicating a +258.74% upside. It includes a peer comparison and mentions that relevant financial forecasting data for EPS, Revenue, EBIT, …

PLYX main company
Sharemaestro market context Stored weekly price path 28 weeks -70.8% · Next-week setup negative 41.0% PLYX stored weekly price path from 6 Feb 2026 to 14 Aug 2026
TradingKey Earnings Main company 🇺🇸 United States

PLYX|Polaryx Therapeutics Ord Shs|Price:2.137|Chg%:-0.013

Polaryx Therapeutics Ord Shs (PLYX) stock closed at $2.31 on July 31st, 2026, up 7.44% for the day, with a market capitalization of $109.36 million. Analysts rate PLYX as a "Buy" with a target price of $8.50, suggesting a significant upside. The article provides …

PLYX main company
Sharemaestro market context Stored weekly price path 28 weeks -70.8% · Next-week setup negative 41.0% PLYX stored weekly price path from 6 Feb 2026 to 14 Aug 2026
Stock Titan Earnings Main company 🇺🇸 United States

Polaryx Therapeutics, Inc. SEC Filing (Jul 28, 2026)

Polaryx Therapeutics, Inc. (PLYX) filed an ARS document with the SEC on July 28, 2026, which was accepted at 5:04 PM ET. This filing has a low impact and neutral sentiment according to AI-generated analysis. The article also provides an overview of recent news …

PLYX main company
Sharemaestro market context Stored weekly price path 28 weeks -70.8% · Next-week setup negative 41.0% PLYX stored weekly price path from 6 Feb 2026 to 14 Aug 2026
Stock Titan Earnings Main company 🇺🇸 United States

Polaryx Therapeutics (PLYX) sets 2026 virtual meeting, director votes and auditor

Polaryx Therapeutics (PLYX) has scheduled its 2026 annual stockholders' meeting for September 10, 2026, to be held virtually. Shareholders will vote on the election of two Class I directors, Alex Yang and Mitchel Berger, and the ratification of Grant Thornton LLP as the independent …

PLYX main company
Sharemaestro market context Stored weekly price path 28 weeks -70.8% · Next-week setup negative 41.0% PLYX stored weekly price path from 6 Feb 2026 to 14 Aug 2026
GuruFocus Analyst action Main company 🇺🇸 United States

PLYX Initiates Coverage On by Lucid Capital Markets -- Rating Set to Buy

Lucid Capital Markets has initiated coverage on Polaryx Therapeutics (PLYX) with a "Buy" rating and a $7.00 price target. This follows similar positive ratings from other analysts, indicating growing confidence in the company, which focuses on rare pediatric lysosomal storage disorders. Despite a low …

PLYX main company
Sharemaestro market context Stored weekly price path 28 weeks -70.8% · Next-week setup negative 41.0% PLYX stored weekly price path from 6 Feb 2026 to 14 Aug 2026
Investing.com Canada Analyst action Main company 🇺🇸 United States

Lucid Capital initiates Polaryx stock with buy rating on rare disease therapy potential

Lucid Capital initiated coverage on Polaryx Therapeutics (NASDAQ:PLYX) with a buy rating and a $7.00 price target, citing the company's potential in developing disease-modifying therapies for rare pediatric lysosomal storage diseases. The firm highlights the Phase 2 SOTERIA basket trial of PLX-200 and its …

PLYX main company
Sharemaestro market context Stored weekly price path 28 weeks -70.8% · Next-week setup negative 41.0% PLYX stored weekly price path from 6 Feb 2026 to 14 Aug 2026
TradingKey Market update Main company 🇺🇸 United States

Polaryx Therapeutics Ord Shs (PLYX) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Polaryx Therapeutics Ord Shs (PLYX), listing major shareholders and their proportional holdings, as well as institutional ownership. Key shareholders include Mstone Partners Healthcare Ltd, Koh (Gershon), Rush University Medical Center, Young Poong Pharmaceutical Co, Ltd., and The …

PLYX main company
Sharemaestro market context Stored weekly price path 28 weeks -70.8% · Next-week setup negative 41.0% PLYX stored weekly price path from 6 Feb 2026 to 14 Aug 2026
TradingView Earnings Main company 🇺🇸 United States

Polaryx Therapeutics, Inc. Revenue Breakdown – BOATS:PLYX

This article provides details on the revenue breakdown for Polaryx Therapeutics, Inc. (PLYX). It outlines where to find financial information and statistical data for the company within the TradingView platform. The content primarily serves as a navigational guide to financial statements, statistics, dividends, earnings, …

PLYX main company
Sharemaestro market context Stored weekly price path 28 weeks -70.8% · Next-week setup negative 41.0% PLYX stored weekly price path from 6 Feb 2026 to 14 Aug 2026
Kalkine Market update Main company 🇺🇸 United States

Polaryx Therapeutics, Inc. Common Stock (NASDAQ: PLYX) Stock Price, News & Analysis

This article provides an overview of Polaryx Therapeutics, Inc. (NASDAQ: PLYX) stock, including its current price, daily range, and a snapshot of its fundamental metrics such as previous close, market capitalization, and trading volume. It also offers sections for financial charts, peer comparison, and …

PLYX main company
Sharemaestro market context Stored weekly price path 28 weeks -70.8% · Next-week setup negative 41.0% PLYX stored weekly price path from 6 Feb 2026 to 14 Aug 2026
www.marketscreener.com Market update Main company 🇺🇸 United States

Polaryx Therapeutics, Inc. Announces Resignation of Lisa Bollinger from Chief Medical Officer, Effective July 19, 2026

Polaryx Therapeutics, Inc. announced the resignation of Lisa Bollinger, MD, as Chief Medical Officer, effective July 19, 2026. The company does not expect her departure to impact its clinical timelines, regulatory plans, or development strategy. A search for a successor has begun, with current …

PLYX main company
Sharemaestro market context Stored weekly price path 28 weeks -70.8% · Next-week setup negative 41.0% PLYX stored weekly price path from 6 Feb 2026 to 14 Aug 2026
Stock Titan Market update Main company 🇺🇸 United States

Polaryx Therapeutics (PLYX) schedules 2026 virtual annual meeting and proposal deadline

Polaryx Therapeutics (PLYX) has announced that its 2026 Annual Meeting of Stockholders will be held virtually on September 10, 2026. The record date for stockholders eligible to vote is July 27, 2026. The deadline for stockholder proposals and director nominations to be included in …

PLYX main company
Sharemaestro market context Stored weekly price path 28 weeks -70.8% · Next-week setup negative 41.0% PLYX stored weekly price path from 6 Feb 2026 to 14 Aug 2026
Bitget Market update Main company 🇺🇸 United States

Polaryx Therapeutics sets 2026 annual shareholder meeting as virtual event

Polaryx Therapeutics has announced that its 2026 annual stockholders meeting will be held virtually on September 10, 2026. Shareholders recorded as of July 27, 2026, will be eligible to vote. The company plans to release further details regarding the matters to be voted upon …

PLYX main company
Sharemaestro market context Stored weekly price path 28 weeks -70.8% · Next-week setup negative 41.0% PLYX stored weekly price path from 6 Feb 2026 to 14 Aug 2026

Find financial news

Search the Newsreel

Use one field or combine several. Results are newest first.

Evidence context